Potentiation of human lung fibroblast chemotaxis by the thromboxane A2 analog U-46619

T. Kohyama, Xiang-de Liu, F. Q. Wen, H. J. Kim, H. Takizawa, S. I. Rennard

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Fibroblast production of extracellular matrix is crucial not only for normal tissue development and maintenance of tissue structure but also for the repair and remodeling processes after injury. Thromboxane A2 (TXA2) is a potent mediator in inflammatory processes. The aim of this study was to investigate the effect of TXA2 on chemotaxis of human fetal lung (HFL-1) fibroblasts induced by human plasma fibronectin or platelet-derived growth factor BB (PDGF-BB). By using the blindwell chamber technique, the TXA2 agonist U-46619 alone had no chemotactic activity. However, U-46619 (200 nmol/L) stimulated HFL-1 fibroblast chemotaxis to human plasma fibronectin (20 μg/mL; 161.8% ± 13.4%; P <.005) and to PDGF-BB (10 ng/mL; 188.5% ± 7.0%; P <.005). Checkerboard analysis of human plasma fibronectin-directed migration confirmed that the TXA2 agonist increased both chemotaxis and chemokinesis. The stimulatory effect of the TXA2 agonist was concentration dependent and increased with time. Another agent known for stimulating the protein kinase C pathway, phorbol 12-myristate 13-acetate (10−8 mol/L), had a similar effect, stimulating chemotaxis to fibronectin (146.2% ± 8.6%). The stimulatory effect of the TXA2 agonist on HFL-1 fibroblast chemotaxis was inhibited by the synthetic thromboxane receptor antagonist SQ29, 548 (10−5 mol/L) and the protein kinase C inhibitor calphostin (10−7 mol/L). In summary, TXA2 appears to stimulate fibroblast chemotaxis to fibronectin and PDGF, perhaps by modulating the rate of fibroblast migration. Such an effect may contribute to regulation of wound healing and the development of fibrotic disorders.

Original languageEnglish (US)
Pages (from-to)43-49
Number of pages7
JournalJournal of Laboratory and Clinical Medicine
Volume139
Issue number1
DOIs
StatePublished - Jan 2002

Fingerprint

15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid
Thromboxane A2
Chemotaxis
Fibroblasts
Fibronectins
Lung
Plasma (human)
Protein Kinase C
Artificial Receptors
Thromboxane Receptors
Tissue
Protein C Inhibitor
Protein Kinase Inhibitors
Wound Healing
Extracellular Matrix
Acetates
Repair
Maintenance
Wounds and Injuries

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Potentiation of human lung fibroblast chemotaxis by the thromboxane A2 analog U-46619. / Kohyama, T.; Liu, Xiang-de; Wen, F. Q.; Kim, H. J.; Takizawa, H.; Rennard, S. I.

In: Journal of Laboratory and Clinical Medicine, Vol. 139, No. 1, 01.2002, p. 43-49.

Research output: Contribution to journalArticle

Kohyama, T. ; Liu, Xiang-de ; Wen, F. Q. ; Kim, H. J. ; Takizawa, H. ; Rennard, S. I. / Potentiation of human lung fibroblast chemotaxis by the thromboxane A2 analog U-46619. In: Journal of Laboratory and Clinical Medicine. 2002 ; Vol. 139, No. 1. pp. 43-49.
@article{20669a26894a4b388e012e1b00b71c8b,
title = "Potentiation of human lung fibroblast chemotaxis by the thromboxane A2 analog U-46619",
abstract = "Fibroblast production of extracellular matrix is crucial not only for normal tissue development and maintenance of tissue structure but also for the repair and remodeling processes after injury. Thromboxane A2 (TXA2) is a potent mediator in inflammatory processes. The aim of this study was to investigate the effect of TXA2 on chemotaxis of human fetal lung (HFL-1) fibroblasts induced by human plasma fibronectin or platelet-derived growth factor BB (PDGF-BB). By using the blindwell chamber technique, the TXA2 agonist U-46619 alone had no chemotactic activity. However, U-46619 (200 nmol/L) stimulated HFL-1 fibroblast chemotaxis to human plasma fibronectin (20 μg/mL; 161.8{\%} ± 13.4{\%}; P <.005) and to PDGF-BB (10 ng/mL; 188.5{\%} ± 7.0{\%}; P <.005). Checkerboard analysis of human plasma fibronectin-directed migration confirmed that the TXA2 agonist increased both chemotaxis and chemokinesis. The stimulatory effect of the TXA2 agonist was concentration dependent and increased with time. Another agent known for stimulating the protein kinase C pathway, phorbol 12-myristate 13-acetate (10−8 mol/L), had a similar effect, stimulating chemotaxis to fibronectin (146.2{\%} ± 8.6{\%}). The stimulatory effect of the TXA2 agonist on HFL-1 fibroblast chemotaxis was inhibited by the synthetic thromboxane receptor antagonist SQ29, 548 (10−5 mol/L) and the protein kinase C inhibitor calphostin (10−7 mol/L). In summary, TXA2 appears to stimulate fibroblast chemotaxis to fibronectin and PDGF, perhaps by modulating the rate of fibroblast migration. Such an effect may contribute to regulation of wound healing and the development of fibrotic disorders.",
author = "T. Kohyama and Xiang-de Liu and Wen, {F. Q.} and Kim, {H. J.} and H. Takizawa and Rennard, {S. I.}",
year = "2002",
month = "1",
doi = "10.1067/mlc.2002.120540",
language = "English (US)",
volume = "139",
pages = "43--49",
journal = "Translational Research",
issn = "1931-5244",
publisher = "Mosby Inc.",
number = "1",

}

TY - JOUR

T1 - Potentiation of human lung fibroblast chemotaxis by the thromboxane A2 analog U-46619

AU - Kohyama, T.

AU - Liu, Xiang-de

AU - Wen, F. Q.

AU - Kim, H. J.

AU - Takizawa, H.

AU - Rennard, S. I.

PY - 2002/1

Y1 - 2002/1

N2 - Fibroblast production of extracellular matrix is crucial not only for normal tissue development and maintenance of tissue structure but also for the repair and remodeling processes after injury. Thromboxane A2 (TXA2) is a potent mediator in inflammatory processes. The aim of this study was to investigate the effect of TXA2 on chemotaxis of human fetal lung (HFL-1) fibroblasts induced by human plasma fibronectin or platelet-derived growth factor BB (PDGF-BB). By using the blindwell chamber technique, the TXA2 agonist U-46619 alone had no chemotactic activity. However, U-46619 (200 nmol/L) stimulated HFL-1 fibroblast chemotaxis to human plasma fibronectin (20 μg/mL; 161.8% ± 13.4%; P <.005) and to PDGF-BB (10 ng/mL; 188.5% ± 7.0%; P <.005). Checkerboard analysis of human plasma fibronectin-directed migration confirmed that the TXA2 agonist increased both chemotaxis and chemokinesis. The stimulatory effect of the TXA2 agonist was concentration dependent and increased with time. Another agent known for stimulating the protein kinase C pathway, phorbol 12-myristate 13-acetate (10−8 mol/L), had a similar effect, stimulating chemotaxis to fibronectin (146.2% ± 8.6%). The stimulatory effect of the TXA2 agonist on HFL-1 fibroblast chemotaxis was inhibited by the synthetic thromboxane receptor antagonist SQ29, 548 (10−5 mol/L) and the protein kinase C inhibitor calphostin (10−7 mol/L). In summary, TXA2 appears to stimulate fibroblast chemotaxis to fibronectin and PDGF, perhaps by modulating the rate of fibroblast migration. Such an effect may contribute to regulation of wound healing and the development of fibrotic disorders.

AB - Fibroblast production of extracellular matrix is crucial not only for normal tissue development and maintenance of tissue structure but also for the repair and remodeling processes after injury. Thromboxane A2 (TXA2) is a potent mediator in inflammatory processes. The aim of this study was to investigate the effect of TXA2 on chemotaxis of human fetal lung (HFL-1) fibroblasts induced by human plasma fibronectin or platelet-derived growth factor BB (PDGF-BB). By using the blindwell chamber technique, the TXA2 agonist U-46619 alone had no chemotactic activity. However, U-46619 (200 nmol/L) stimulated HFL-1 fibroblast chemotaxis to human plasma fibronectin (20 μg/mL; 161.8% ± 13.4%; P <.005) and to PDGF-BB (10 ng/mL; 188.5% ± 7.0%; P <.005). Checkerboard analysis of human plasma fibronectin-directed migration confirmed that the TXA2 agonist increased both chemotaxis and chemokinesis. The stimulatory effect of the TXA2 agonist was concentration dependent and increased with time. Another agent known for stimulating the protein kinase C pathway, phorbol 12-myristate 13-acetate (10−8 mol/L), had a similar effect, stimulating chemotaxis to fibronectin (146.2% ± 8.6%). The stimulatory effect of the TXA2 agonist on HFL-1 fibroblast chemotaxis was inhibited by the synthetic thromboxane receptor antagonist SQ29, 548 (10−5 mol/L) and the protein kinase C inhibitor calphostin (10−7 mol/L). In summary, TXA2 appears to stimulate fibroblast chemotaxis to fibronectin and PDGF, perhaps by modulating the rate of fibroblast migration. Such an effect may contribute to regulation of wound healing and the development of fibrotic disorders.

UR - http://www.scopus.com/inward/record.url?scp=0036009002&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036009002&partnerID=8YFLogxK

U2 - 10.1067/mlc.2002.120540

DO - 10.1067/mlc.2002.120540

M3 - Article

C2 - 11873244

AN - SCOPUS:0036009002

VL - 139

SP - 43

EP - 49

JO - Translational Research

JF - Translational Research

SN - 1931-5244

IS - 1

ER -